New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
January 28, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings showed robu...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Reduced-dose RT with Cisplatin improves outcomes for HPV-associated oropharyngeal carcinoma
(NRG Oncology) A combination of reduced-dose radiotherapy using intensity-modulated radiotherapy (IMRT) combined with concurrent cisplatin met the threshold for disease control and quality of life compared to the standard of care for good-risk patients with HPV-associated oropharyngeal squamous cell carcinoma on the NRG Oncology clinical trial NRG-HN002. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2021 Category: Cancer & Oncology Source Type: news
Does Squamous Cell Cancer Turn into Melanoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 26, 2021 Category: General Medicine Source Type: news
Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of standard of c...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Oncotarget: PD-1/PD-L1 expression in anal squamous intraepithelial lesions
(Impact Journals LLC) Dr. Margot Bucau from The H ô pital Bichat-Claude Bernard said, " Anal intraepithelial neoplasia (AIN) is the precursor lesion for anal squamous cell carcinomas (ASCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news
Proteogenomics offers insight to treating head and neck squamous cell carcinoma
(Baylor College of Medicine) A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 7, 2021 Category: International Medicine & Public Health Source Type: news
Researchers aim AI at rising oral cancers with $3.3M grant from National Cancer Institute
(Case Western Reserve University) Researchers at Case Western Reserve University and partners in the United States and India are applying artificial intelligence (AI) to help physicians customize treatments for patients with the most common oral cancer, known as squamous cell carcinomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news
Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
SAN MATEO, Calif., Dec. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 ... Biopharmaceuticals, Oncology Rakuten Medical, photoimmunotherapy, Illuminox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2020 Category: Pharmaceuticals Source Type: news
Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The application marks the first-ever regulatory submission for the treatment of patients with NSCLC with EGFR exon 20 insertion mutations.[1] The Company has...
Source: Johnson and Johnson - December 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Scientists regenerate skin with stem cells to see how DNA defects in kids cause cancer
(Cincinnati Children's Hospital Medical Center) Physicians and scientists at Cincinnati Children's Hospital Medical Center used new stem cell technology to regenerate and study living patient-specific skin in the lab, giving them a precise close up view of how inherited DNA defects cause skin damage and deadly squamous cell carcinoma in children and young adults with Fanconi anemia (FA). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 23, 2020 Category: Cancer & Oncology Source Type: news
First-ever phase 3 clinical trial opens for patients with advanced anal cancer
(ECOG-ACRIN Cancer Research Group) A new clinical trial for metastatic anal cancer will determine if a drug that uses the immune system to fight cancer will prolong progression-free survival when given with standard chemotherapy. Study EA2176 will enroll 205 patients in the US with inoperable advanced (spread to other parts of the body) squamous cell anal cancer. Eligibility includes newly diagnosed patients who have not yet started treatment and patients whose cancer has returned/worsened following surgery or radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 16, 2020 Category: Cancer & Oncology Source Type: news
Icotinib Plus Radiotherapy Ups Survival in Elderly With Esophageal Cancer Icotinib Plus Radiotherapy Ups Survival in Elderly With Esophageal Cancer
Icotinib with concurrent radiotherapy (RT) boosts survival and may have other benefits compared to RT alone in elderly patients with unresectable esophageal squamous cell carcinoma, according to Chinese researchers.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 19, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Can Squamous Cell Carcinoma Spread to Lymph Nodes?
Title: Can Squamous Cell Carcinoma Spread to Lymph Nodes?Category: Diseases and ConditionsCreated: 10/15/2020 12:00:00 AMLast Editorial Review: 10/15/2020 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - October 15, 2020 Category: Dermatology Source Type: news
Black lives also matter in cancer care
(University of Colorado Anschutz Medical Campus) It is not biology, but access to health care that is causing Black Non-Hispanic patients with squamous cell cancer of the head and neck to have lower survival rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 1, 2020 Category: Cancer & Oncology Source Type: news
New vulnerability found in lung squamous cancer may facilitate drug targeting
(UNC Lineberger Comprehensive Cancer Center) New cancer research by scientists at UNC Lineberger Comprehensive Cancer Center, and colleagues, shows the potential for targeting a specific circular RNA, known as CDR1as, to attack lung squamous cell cancer. Lung squamous cell cancers comprise up to 30% of all lung cancers and are responsible for about 70,000 new cases and approximately 40,000 deaths each year in the U.S. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2020 Category: Cancer & Oncology Source Type: news
